News

Investors Show Bearish Sentiment Towards Regeneron Options

Investors Show Bearish Sentiment Towards Regeneron Options

Market Participants Take Note of Regeneron Pharmaceuticals Options

Investors are closely watching the recent moves concerning Regeneron Pharmaceuticals (NASDAQ: REGN) as wealthy market players display a noticeable bearish sentiment. This shift in options trading patterns is something that market participants need to take seriously. These major trades signal anticipation for impactful changes ahead regarding REGN.

Recent observations from options activity reveal a significant uptick in transactions, with 8 unusual options activities identified. Such a level of trading volume typically precedes noteworthy events in the company.

Assessing the Current Rate of Price Movement

Recent analyses show that key market influencers are concentrating on guiding REGN's price within a range of $530.0 to $1095.0 during the last few months. This range signifies levels that traders are particularly focused on.

Volume and Open Interest Insight

Today's options trading indicates a mean open interest of 92.17 for REGN. The total volume of options associated with Regeneron stands at 41.00, a clear indication of active market interest.

Important Options Trading Details

Monitoring recent trades over the past month, it becomes apparent where significant trades have landed. The trading behavior for options on REGN illustrates how traders are navigating their positions within the market.

Noteworthy Options Trades

During our tracking, we've detected several key trades that highlight market trends:

  • Symbol: REGN
    Type: PUT
    Trade Type: TRADE
    Sentiment: BEARISH
    Expiration Date: 12/18/26
    Price: $122.0
    Strike Price: $950.00
    Total Trade Price: $61.0K
    Open Interest: 55
    Volume: 10
  • Symbol: REGN
    Type: PUT
    Trade Type: TRADE
    Sentiment: BEARISH
    Expiration Date: 12/18/26
    Price: $122.0
    Strike Price: $950.00
    Total Trade Price: $61.0K
    Open Interest: 55
    Volume: 5
  • Symbol: REGN
    Type: CALL
    Trade Type: TRADE
    Sentiment: NEUTRAL
    Expiration Date: 05/16/25
    Price: $35.4
    Strike Price: $1095.00
    Total Trade Price: $49.5K
    Open Interest: 15
    Volume: 14
  • Symbol: REGN
    Type: CALL
    Trade Type: TRADE
    Sentiment: BULLISH
    Expiration Date: 12/18/26
    Price: $483.1
    Strike Price: $530.00
    Total Trade Price: $48.3K
    Open Interest: 3
    Volume: 0
  • Symbol: REGN
    Type: CALL
    Trade Type: TRADE
    Sentiment: NEUTRAL
    Expiration Date: 02/21/25
    Price: $91.9
    Strike Price: $920.00
    Total Trade Price: $45.9K
    Open Interest: 17
    Volume: 5

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is dedicated to discovering and producing innovative products aimed at treating conditions such as eye diseases, cardiovascular issues, cancers, and inflammatory disorders. Among their well-known products are Eylea for age-related macular degeneration, Praluent for lowering LDL cholesterol, Dupixent for various immunology conditions, Libtayo for cancer treatment, and Kevzara for rheumatoid arthritis. Furthermore, Regeneron actively engages in developing advanced therapies in collaboration with other entities, focusing on cutting-edge technologies including CRISPR gene editing.

Current Status of Regeneron Pharmaceuticals

  • Trading volume stands at 96,123, with REGN showing a decline of -2.34% and settling at $939.78.
  • Relative Strength Index (RSI) indicates the stock might be undersold at present.
  • The upcoming earnings report is anticipated shortly.

Analyst Insights on Regeneron Pharmaceuticals

In the past month, a cohort of five industry analysts shared their evaluations regarding REGN, predicting an average target price around $1155.2.

While options trading carries its set of risks, it can also yield higher rewards. Experienced options traders utilize various strategies including education, diligent monitoring of market trends, and smart entry and exit tactics to mitigate risks associated with their trades.

To keep abreast of the latest options activity for Regeneron Pharmaceuticals, real-time alerts and updates are available through services that cater specifically to options traders.

Frequently Asked Questions

What is the current sentiment among Regeneron investors?

The sentiment appears bearish, with a significant portion of options trades indicating potential downward trends.

What is the recent price range for Regeneron’s stocks?

The stock's price is currently trading between $530.0 and $1095.0, showcasing volatility in recent months.

How many options have been traded for Regeneron recently?

Recent activity indicates 8 notable options movements, signaling heightened trading interest.

What are Regeneron's primary products?

Key products include Eylea, Praluent, Dupixent, Libtayo, and Kevzara, addressing various medical conditions.

What do analysts predict for Regeneron's stock?

Analyst averages suggest a target price of approximately $1155.2, reflecting a mix of optimism and caution based on market conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Mastering Technical Analysis for Leading Tech Stocks Today

Updated Category News Views 148

Understanding the Market Landscape Good morning, traders! Today’s economic landscape presents a relatively quiet day on the calendar. Key data releases will emerge around 8:30 AM, including initial and continuing jobless claims, along with trade balance figures. As we dive into the trading session, market participants will also keep a close eye on Treasury...

Continue Reading
Overview of Orion Corporation's Key Financial Events in 2026

Updated Category News Views 338

Orion Corporation's Financial Reporting Schedule for 2026 Orion Corporation is gearing up to share its financial performance with its stakeholders in 2026. The company plans to publish its Financial Statement Release for the year 2025 on Thursday, 12 February 2026. Financial transparency is crucial for maintaining trust, and Orion is committed to keeping its investors...

Continue Reading
Commvault's Strategic Capital Raise with Convertible Bonds

Updated Category News Views 226

Commvault's Convertible Senior Notes Offering Recently, Commvault Systems, Inc. (NASDAQ: CVLT) revealed an upsized private offering for a substantial $785 million in 0% Convertible Senior Notes. These notes are due in 2030 and represent a strategic maneuver to bolster the company's financial position. The offering's increased size from an originally proposed $750 million...

Continue Reading
Innovative Upgrades from Telnyx Transform Voice AI Technology

Updated Category News Views 213

Transforming the Voice AI Landscape Telnyx is a well-respected leader in communications infrastructure, and its recent updates to the Voice AI stack illustrate its commitment to innovation. With a variety of new features aimed at enhancing user experience and interaction quality, Telnyx is truly transforming how businesses can engage in voice communications. The latest...

Continue Reading
Nykredit Realkredit A/S Publishes Key Debtor Distribution Insights

Updated Category News Views 46

Comprehensive Overview of Debtor Distribution Data Nykredit Realkredit A/S recently announced significant updates regarding its callable mortgage bond series. The company regularly contributes valuable information to investors and stakeholders, ensuring transparency and confidence in its operational metrics. This announcement pertains to the debtor distribution data as of...

Continue Reading